Rajakumar Nagarajan1, Michael Albert Thomas1, Whitney B. Pope1, Robert M. Prins2, Neil Wilson1, Noriko Salamon1, Linda M. Liau2
The mutation observed in the isocitrate dehydrogenase1 (IDH1) gene, which occurs in the majority of grade II and grade III gliomas and secondary glioblastomas shows significant elevation of 2-hydroxyglutarate (2HG) in the brain tumors. We have quantified 2HG in the brain tumor patients using proton (1H) MR spectra recorded on a 3T MRI/MRS scanner and post-processed by LC-model algorithm. In this study, we show increased 2HG in the mutant type compared to wild type tumors. 1H MRS enables a non-invasive measure of 2HG in gliomas, which may serve as a potential biomarker for monitoring patients with IDH1 mutant brain tumors.